000294422 001__ 294422
000294422 005__ 20241107160244.0
000294422 0247_ $$2doi$$a10.1093/neuonc/noy059.574
000294422 0247_ $$2ISSN$$a1522-8517
000294422 0247_ $$2ISSN$$a1523-5866
000294422 037__ $$aDKFZ-2024-02251
000294422 041__ $$aEnglish
000294422 082__ $$a610
000294422 1001_ $$aBrabetz, Sebastian$$b0
000294422 245__ $$aPCLN-05. A BIOBANK OF PATIENT-DERIVED MOLECULARLY CHARACTERIZED ORTHOTOPIC PEDIATRIC BRAIN TUMOR MODELS FOR PRECLINICAL RESEARCH
000294422 260__ $$aOxford$$bOxford Univ. Press$$c2018
000294422 3367_ $$2DRIVER$$aarticle
000294422 3367_ $$2DataCite$$aOutput Types/Journal article
000294422 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730991698_24841
000294422 3367_ $$2BibTeX$$aARTICLE
000294422 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294422 3367_ $$00$$2EndNote$$aJournal Article
000294422 520__ $$aIdentification of multiple distinct subtypes of pediatric brain tumors raises the need for more and better preclinical models reflecting these subtypes. Orthotopic patient-derived xenograft (PDX) models generated by injection of human tumor cells into the brain of NSG mice offer the unique possibility to test novel substances in primary patient tissue in an in vivo environment. Extensive molecular characterization of PDX and matching primary tumor/blood are needed to see how well the PDX represents the original disease, to learn about targetable oncogenic drivers in each model, and to establish or confirm predictive biomarkers. In an ongoing world-wide effort we have generated and fully characterized thus far 130 PDX models reflecting 22 distinct molecular subtypes of pediatric brain tumors. PDX models always retain their molecular subtype as assessed by DNA methylation analysis and in the vast majority of cases also the mutations and copy number alterations when compared to their primary tumors. Most aggressive tumors, such as those having MYC(N) amplifications, are overrepresented in the cohort, but also subtypes which have not been available for preclinical testing before due to lack of genetically engineered mouse models or suitable cell lines are included. All models and corresponding molecular data will become available for the community for preclinical research. Our repertoire of PDX models and corresponding molecular characterizations allow researchers to find the right models for their specific scientific questions. It provides an unprecedented resource to study tumor biology and paves the way for improving treatment strategies for children with malignant brain tumors.
000294422 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000294422 7001_ $$aGroebner, Susanne N$$b1
000294422 7001_ $$aJaeger, Natalie$$b2
000294422 7001_ $$aMilde, Till$$b3
000294422 7001_ $$aEcker, Jonas$$b4
000294422 7001_ $$aSelt, Florian$$b5
000294422 7001_ $$aWitt, Olaf$$b6
000294422 7001_ $$aRusert, Jessica M$$b7
000294422 7001_ $$aKoster, Jan$$b8
000294422 7001_ $$aLeary, Sarah E$$b9
000294422 7001_ $$aLi, Xiao-Nan$$b10
000294422 7001_ $$aWechsler-Reya, Robert J$$b11
000294422 7001_ $$aOlson, James M$$b12
000294422 7001_ $$aPfister, Stefan M$$b13
000294422 7001_ $$aKool, Marcel$$b14
000294422 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noy059.574$$gVol. 20, no. suppl_2, p. i155 - i155$$nsuppl_2$$pi155 - i155$$tNeuro-Oncology$$v20$$x1522-8517$$y2018
000294422 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000294422 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000294422 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294422 9801_ $$aEXTERN4VITA
000294422 980__ $$ajournal
000294422 980__ $$aEDITORS
000294422 980__ $$aI:(DE-He78)W510-20160331
000294422 980__ $$aI:(DE-He78)W500-20160331